A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

about

Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice.The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Type 2 immunity in asthma.

P2860

Q49603082-BE00430B-54AF-47C7-AC1E-D57564859D58 Q52332667-4B1FFE60-3537-4C85-BEC0-918C919AAB5C Q55332823-BE3BF478-2C75-49A1-BDF0-CF1E2F4A9AD5 Q55454410-F1BC7977-E555-4676-BF5F-F5075B867A88

P2860

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

Item

http://www.wikidata.org/entity/Q38634828

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A Phase 2 Randomized Controlle ...... Idiopathic Pulmonary Fibrosis.

@en

type

Item

label

A Phase 2 Randomized Controlle ...... Idiopathic Pulmonary Fibrosis.

@en

prefLabel

A Phase 2 Randomized Controlle ...... Idiopathic Pulmonary Fibrosis.

@en

P1476

A Phase 2 Randomized Controlle ...... Idiopathic Pulmonary Fibrosis.

@en

P2093

Chris M Kell

http://www.w3.org/2001/XMLSchema#string

Dewei She

http://www.w3.org/2001/XMLSchema#string

Ethan P Grant

http://www.w3.org/2001/XMLSchema#string

Ian N Glaspole

http://www.w3.org/2001/XMLSchema#string

Jon P Fiening

http://www.w3.org/2001/XMLSchema#string

Joseph M Parker

http://www.w3.org/2001/XMLSchema#string

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

Lisa H Lancaster

http://www.w3.org/2001/XMLSchema#string

Stephanie L Roseti

http://www.w3.org/2001/XMLSchema#string

Tarik J Haddad

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

Recent advances in understanding idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Pulmonary fibrosis: pathogenesis, etiology and regulation

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis

P31

scholarly article

P356

10.1164/RCCM.201704-0784OC

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28787186

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

about

P2860

P2860

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698

P921